Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.

Leukemia - 1 Jul 2014

Tefferi A, Guglielmelli P, Lasho T L, Rotunno G, Finke C, Mannarelli C, Belachew A A, Pancrazzi A, Wassie E A, Ketterling R P, Hanson C A, Pardanani A, Vannucchi A M

Abstract excerpt

Current prognostication in primary myelofibrosis (PMF) is based on the dynamic international prognostic scoring system (DIPSS)-plus, which employs clinical and cytogenetic variables. We recently reported DIPSS-plus independent prognostic significance for calreticulin (CALR) (favorable) and ASXL1 (unfavorable) mutations. In the current study, 570 PMF patients were recruited for derivation (n=277) and validation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Calreticulin

Share to Cohort Studies

Share to Phenotype

Share to Primary Myelofibrosis

Share to Prognosis

Share to Repressor Proteins

Source

Identifiers

PMID: 24496303
DOI: 10.1038/leu.2014.57

Genes

ASXL1
CALR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.PMID 24496303Read ↗

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.Semantic proximity Read ↗

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosisSemantic proximity Read ↗

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.Semantic proximity Read ↗

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.Semantic proximity Read ↗

Prognosis of Primary Myelofibrosis in the Genomic Era.Semantic proximity Read ↗

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.Semantic proximity Read ↗

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.Semantic proximity Read ↗

Improved survival in patients with CALR1 compared to CALR2 mutated primary myelofibrosis: a meta-analysis.Semantic proximity Read ↗

Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary MyelofibrosisSemantic proximity Read ↗

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impactSemantic proximity Read ↗

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.Semantic proximity Read ↗

The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.